Trial Profile

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azenosertib (Primary) ; Niraparib (Primary)
Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms MAMMOTH
Sponsors K-Group Beta; Zentalis Pharmaceuticals

Most Recent Events

29 Jan 2025 Results presented in the Zentalis Pharmaceuticals media release.
23 Sep 2024 Planned number of patients changed from 138 to 140.
24 Jun 2024 Planned End Date changed from 1 Nov 2023 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com